Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

1.

Neutralization serotyping of BK polyomavirus infection in kidney transplant recipients.

Pastrana DV, Brennan DC, Cuburu N, Storch GA, Viscidi RP, Randhawa PS, Buck CB.

PLoS Pathog. 2012;8(4):e1002650. doi: 10.1371/journal.ppat.1002650.

2.

BK polyomavirus genotypes represent distinct serotypes with distinct entry tropism.

Pastrana DV, Ray U, Magaldi TG, Schowalter RM, Çuburu N, Buck CB.

J Virol. 2013 Sep;87(18):10105-13. doi: 10.1128/JVI.01189-13. Erratum in: J Virol. 2016 Jan 1;90(1):624.

3.

Immunity to Polyomavirus BK Infection: Immune Monitoring to Regulate the Balance between Risk of BKV Nephropathy and Induction of Alloimmunity.

Comoli P, Cioni M, Basso S, Gagliardone C, Potenza L, Verrina E, Luppi M, Zecca M, Ghiggeri GM, Ginevri F.

Clin Dev Immunol. 2013;2013:256923. doi: 10.1155/2013/256923. Review.

4.

Interplay of cellular and humoral immune responses against BK virus in kidney transplant recipients with polyomavirus nephropathy.

Chen Y, Trofe J, Gordon J, Du Pasquier RA, Roy-Chaudhury P, Kuroda MJ, Woodle ES, Khalili K, Koralnik IJ.

J Virol. 2006 Apr;80(7):3495-505.

5.

Polyomavirus-associated nephropathy: update on BK virus-specific immunity.

Comoli P, Binggeli S, Ginevri F, Hirsch HH.

Transpl Infect Dis. 2006 Jun;8(2):86-94. Review.

PMID:
16734631
6.

Inflammatory activation and recovering BKV-specific immunity correlate with self-limited BKV replication after renal transplantation.

Schachtner T, Stein M, Sefrin A, Babel N, Reinke P.

Transpl Int. 2014 Mar;27(3):290-301. doi: 10.1111/tri.12251.

7.

Polyomavirus BK neutralizing activity in human immunoglobulin preparations.

Randhawa PS, Schonder K, Shapiro R, Farasati N, Huang Y.

Transplantation. 2010 Jun 27;89(12):1462-5.

8.

Ciprofloxacin prophylaxis in kidney transplant recipients reduces BK virus infection at 3 months but not at 1 year.

Wojciechowski D, Chanda R, Chandran S, Lee B, Webber A, Macaraig M, Tomlanovich S, Vincenti F.

Transplantation. 2012 Dec 15;94(11):1117-23. doi: 10.1097/TP.0b013e31826ec74e.

PMID:
23060281
9.

Serologic studies of papovavirus infections in pregnant women and renal transplant recipients.

Andrews CA, Daniel RW, Shah KV.

Prog Clin Biol Res. 1983;105:133-41.

PMID:
6304749
10.

Cellular immune responses to BK virus.

Comoli P, Hirsch HH, Ginevri F.

Curr Opin Organ Transplant. 2008 Dec;13(6):569-74. doi: 10.1097/MOT.0b013e3283186b93. Review.

PMID:
19060544
11.

Prospective monitoring of polyomavirus BK replication and impact of pre-emptive intervention in pediatric kidney recipients.

Ginevri F, Azzi A, Hirsch HH, Basso S, Fontana I, Cioni M, Bodaghi S, Salotti V, Rinieri A, Botti G, Perfumo F, Locatelli F, Comoli P.

Am J Transplant. 2007 Dec;7(12):2727-35.

12.

Genotypic diversity of polyomaviruses circulating among kidney transplant recipients in Kuwait.

Chehadeh W, Nampoory MR.

J Med Virol. 2013 Sep;85(9):1624-31. doi: 10.1002/jmv.23639.

PMID:
23775307
13.

BK virus-specific immunity kinetics: a predictor of recovery from polyomavirus BK-associated nephropathy.

Schachtner T, Müller K, Stein M, Diezemann C, Sefrin A, Babel N, Reinke P.

Am J Transplant. 2011 Nov;11(11):2443-52. doi: 10.1111/j.1600-6143.2011.03693.x.

14.

Human polyomavirus type 1 (BK virus) agnoprotein is abundantly expressed but immunologically ignored.

Leuenberger D, Andresen PA, Gosert R, Binggeli S, Ström EH, Bodaghi S, Rinaldo CH, Hirsch HH.

Clin Vaccine Immunol. 2007 Aug;14(8):959-68.

15.

Viral Origin, Clinical Course, and Renal Outcomes in Patients With BK Virus Infection After Living-Donor Renal Transplantation.

Schwarz A, Linnenweber-Held S, Heim A, Framke T, Haller H, Schmitt C.

Transplantation. 2016 Apr;100(4):844-53. doi: 10.1097/TP.0000000000001066.

PMID:
26720302
16.

BK polyomavirus infection and nephropathy: the virus-immune system interplay.

Babel N, Volk HD, Reinke P.

Nat Rev Nephrol. 2011 May 24;7(7):399-406. doi: 10.1038/nrneph.2011.59. Review.

PMID:
21610680
17.

Monthly screening for BK viremia is an effective strategy to prevent BK virus nephropathy in renal transplant recipients.

Alméras C, Vetromile F, Garrigue V, Szwarc I, Foulongne V, Mourad G.

Transpl Infect Dis. 2011 Apr;13(2):101-8. doi: 10.1111/j.1399-3062.2011.00619.x.

PMID:
21371220
18.

Polyomavirus BK-specific immunity after kidney transplantation.

Comoli P, Azzi A, Maccario R, Basso S, Botti G, Basile G, Fontana I, Labirio M, Cometa A, Poli F, Perfumo F, Locatelli F, Ginevri F.

Transplantation. 2004 Oct 27;78(8):1229-32.

PMID:
15502726
19.

Different risk factor profiles distinguish early-onset from late-onset BKV-replication.

Schachtner T, Babel N, Reinke P.

Transpl Int. 2015 Sep;28(9):1081-91. doi: 10.1111/tri.12601.

20.

Antibody responses to recombinant polyomavirus BK large T and VP1 proteins in young kidney transplant patients.

Bodaghi S, Comoli P, Bösch R, Azzi A, Gosert R, Leuenberger D, Ginevri F, Hirsch HH.

J Clin Microbiol. 2009 Aug;47(8):2577-85. doi: 10.1128/JCM.00030-09.

Items per page

Supplemental Content

Support Center